Pakistan earns $10m from phase 3 trials of CanSino

ISLAMABAD: The National Institute of Health (NIH) Executive Director Major General Aamer Ikram has revealed that Pakistan earned a whopping $10m from conducting phase 3 trials of the Chinese vaccine CanSino.

The NIH has played an important role in the efforts to check dissemination of coronavirus under the General who was speaking at a function where he disclosed that many countries wanted to hold their phase 3 trials in Pakistan. “These experiments can bring millions of dollars into Pakistan,” he said.

Major General Aamer Ikram said that Pakistan had also started co-manufacturing the single-dose Adenovirus-vectored Covid-19 vaccine with CanSino Bio at the NIH Islamabad, and claimed that within a year, they were hopeful of earning around $30 million through the joint manufacturing of the vaccine in the country. “And this successful venture has opened doors of numerous more such opportunities for Pakistan and now several biotechnological companies from the UK, Korea, Japan and of course China are willing to conduct Phase-III clinical trials of their vaccines in Pakistan,” he said.